NCT06392386 - A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Generalized Myasthenia Gravis

Interventions

BIOLOGICAL

Efgartigimod PH20 SC

Subcutaneous injections

Trial Locations (17)

1011

RECRUITING

Hôpital Nestlé, Lausanne

9000

RECRUITING

UZ Gent, Ghent

13385

RECRUITING

AP-HM- Hôpital de La Timone, Marseille

16147

RECRUITING

Istituto G Gaslini Ospedale Pediatrico IRCCS, Genova

22903

RECRUITING

University of Virginia, Charlottesville

28207

RECRUITING

Carolinas HealthCare System Neurosciences Institute - Neurology, Charlotte

45147

RECRUITING

Universitätsklinikum Essen, Essen

46026

RECRUITING

Hospital Universitari i Politecnic La Fe de Valencia, Valencia

76208

RECRUITING

Neurology Rare Disease Center, Denton

4920235

RECRUITING

Schneider Children's Medical Center of Israel, Petah Tikvah

6423906

RECRUITING

Tel Aviv Sourasky Medical Center Ichilov, Tel Aviv

9112001

RECRUITING

Hadassah Medical Center- Ein Kerem, Jerusalem

613 00

RECRUITING

Fakultni nemocnice Brno, Brno

708 00

RECRUITING

Fakultni nemocnice Ostrava, Ostrava

2333 ZA

RECRUITING

Leiden University Medical Center, Leiden

40-689

RECRUITING

Neurologia Śląska Centrum Medyczne, Katowice

OX3 9DU

RECRUITING

Oxford Children's Hospital, Oxford